July 16, 2021 -- GlaxoSmithKline (GSK) has announced plans to develop a more than 1 million-sq-ft life science campus research and development campus in Stevenage, England.
The idea of the facility was prompted by the company's partnership with Stevenage Bioscience Catalyst, the U.K. government, and the Stevenage Borough Council. GSK plans to sell 33 acres of land in the area to raise 400 million pounds sterling ($551 million U.S.); the land purchaser would develop the new campus, it said. The facility could create up to 5,000 life science research and development jobs over the next five to 10 years.
The Cell and Gene Therapy Catapult and Stevenage Bioscience Catalyst are both already on the site and have attracted a number of successful start-ups which collectively have raised around 1.6 billion pounds ($2.2 billion) of funding, according to the firm.
GSK plans to choose a development partner later this year and to begin planning for the facility in 2022, according to the firm.